<p>*EORTC and NCIC trial 26981-22981/CE.3 population 3: GBM patients who underwent partial or complete resection and were assigned temozolomide and radiotherapy in the presence of an <i>MGMT</i> promoter methylation assessment.</p><p>Patients demographic and clinical characteristics.</p